Updated: Lilly reports mid-stage win for tirzepatide in fatty liver disease MASH
Eli Lilly announced Tuesday that its diabetes and weight loss drug tirzepatide succeeded in a Phase II study for MASH, or metabolic dysfunction-associated steatohepatitis.
At all doses, Lilly reported that tirzepatide had a greater proportion of patients who had no MASH at one year with no worsening in the scarring in their livers. At the low dose of 5 mg of tirzepatide, 51.8% of patients met the primary endpoint, while at the high dose of 15 mg, 73.9% did. At the middle dose of 10 mg, 63.1% of patients hit the mark. In the placebo group, just 12.6% hit the same endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
